SuperGen, Inc. Receives U.S. Patent For Nipent(R)(Pentostatin For Injection)
DUBLIN, Calif., June 2 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced the issuance of U.S. Patent No. 7,037,900 B2 entitled, "Composition and Method for Treating Graft-versus-Host Disease." The patent contains 39 claims relating to the composition and methods for treating graft-versus-host disease (GvHD) and, more specifically, to the administration of inhibitors of adenosine deaminase (ADA). In particular, novel formulations of ADA inhibitors such as pentostatin are utilized for suppressing T-lymphocyte mediated immune responses while minimizing systemic toxicity of the drug.
"This is SuperGen's first patent relating to the use of Nipent(R) in graft-versus-host disease, and it enhances the potential value of our franchise beyond the current approved indication of Hairy Cell Leukemia," said Edward L. Jacobs, Chief Operating Officer. "Nipent(R) is being studied in a large number of trials in a variety of clinical settings. This patent supports the ongoing efforts of clinical investigators to explore further Nipent's utility in GvHD."
Nipent(R) (pentostatin for injection) is currently approved as a single-agent treatment for patients with Hairy Cell Leukemia, and is not approved as either a single agent or as part of a combination regimen for treatment for any other indication.
About Graft -versus -Host Disease (GvHD)
GvHD is a condition that results when the immune cells of a transplant (usually of bone marrow) from a donor attack the tissues of the person receiving the transplant.
Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, and Surface Safe(R) cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit http://www.supergen.com .
This press release contains "forward-looking" statements within the meaning of section 21A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. Such forward-looking statements include statements regarding Nipent's potential use in the treatment of GVHD. Whether or not Nipent may be used in the treatment of GVHD will depend on a number of known and unknown risk factors and uncertainties. Such factors include, but are not limited to, risks and uncertainties related to conducting and completing clinical trials in patients with GVHD, and whether the company will submit or receive regulatory approval for Nipent for the treatment of GVHD. References made to the discussion of the risk factors are detailed in the company's filing with the Securities and Exchange Commission, including the report on Form 10-Q for the quarter ended March 31, 2006. These forward-looking statements are made only as of the date hereof, and the company disclaims any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: SuperGen Noonan Russo Timothy L. Enns Sharon Weinstein S.V.P., Corporate Communications Director of Investor Relations & Business Development Tel: (212) 845-4271 Tel: (925) 560-0100 x111 E-mail: email@example.com E-mail: firstname.lastname@example.orgSuperGen, Inc.
CONTACT: Timothy L. Enns,S.V.P., Corporate Communications & BusinessDevelopment, SuperGen, +1-925-560-0100 ext. 111, email@example.com; orSharon Weinstein, Director of Investor Relations, +1-212-845-4271,firstname.lastname@example.org
Web site: http://www.supergen.com/